+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 9 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating multiple investigational therapies in adult participants with moderately to severely active Crohns Disease or Ulcerative Colitis, which are types of Inflammatory Bowel Disease IBD. This Phase 2 platform study aims to assess the safety, effectiveness, how the body processes the drugs, and their effects on the disease. The study is sponsored by Mirador Therapeutics, Inc. and is designed to explore several oral or intravenous experimental treatments. Participants will be assigned to receive one of several treatments including MT-501 tablets or multiple intravenous doses of MT-201 combined with standard care. Different groups will receive these therapies to compare their effects. The treatment period lasts up to 13 weeks, during which participants will be closely monitored for responses and side effects. During the study, participants will undergo assessments including endoscopy and clinical evaluations to measure disease activity and response. Laboratory tests will monitor safety, and pharmacokinetics will track how the drugs are absorbed and processed. Researchers will observe treatment side effects and disease improvement using specific clinical and endoscopic measures over 12 to 13 weeks. The total participation duration corresponds to the treatment and monitoring period outlined.

Age: 18Years - 80YearsAll GendersPhase 2
66 locations
P

Actively Recruiting

The trial investigates the effectiveness and safety of two dosing schedules of pegozafermin compared to a placebo in adults with metabolic dysfunction-associated steatohepatitis MASH who have liver fibrosis stages F2 or F3. This phase 3 study focuses on people aged 18 to 80 years and aims to better understand treatment options for this liver condition. Participants will be randomly assigned to receive one of two pegozafermin regimens or a matching placebo. Both pegozafermin and placebo are given by subcutaneous injection. The study includes a treatment period lasting up to 52 weeks, during which the effects of these regimens on liver fibrosis and steatohepatitis will be assessed. Throughout the study, participants will undergo various evaluations including liver biopsies, blood tests measuring liver enzymes and fibrosis markers, and monitoring for disease progression for up to five years. Researchers will track improvements in liver fibrosis, resolution of steatohepatitis, changes in liver enzyme levels, and fibrosis scores to assess the impact of the treatments.

Age: 18Years - 80YearsAll GendersPhase 3
370 locations
E

Actively Recruiting

Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.

Age: 18Years - 80YearsAll GendersPhase 4
101 locations
P

Actively Recruiting

Researchers are studying the effectiveness and safety of Afimkibart as an induction and maintenance treatment for people with moderately to severely active Crohns disease. This Phase III, multicenter, double-blind, placebo-controlled study aims to evaluate how well Afimkibart works compared to a placebo in managing this condition. Participants will be randomly assigned to receive either Afimkibart or a placebo. Those receiving Afimkibart will get an intravenous IV infusion followed by subcutaneous SC injections. The study includes two experimental groups receiving Afimkibart and one group receiving placebo, both administered by IV and SC methods. The treatment and follow-up period extends through 52 weeks to assess both induction and maintenance therapy effects. During the study, participants will undergo evaluations including the Crohns Disease Activity Index CDAI for clinical remission and endoscopic assessments at week 52. Additional measurements at week 12 and throughout the study include symptom tracking, stool frequency, abdominal pain, quality of life questionnaires, and monitoring of adverse events. The total study duration may extend up to 70 weeks for safety follow-up and outcome assessments.

Age: 16Years - 80YearsAll GendersPhase 3
375 locations
P

Actively Recruiting

Researchers are evaluating the efficacy and safety of pegozafermin in adults aged 18 to 75 years who have biopsy-confirmed and clinically confirmed compensated cirrhosis caused by metabolic dysfunction-associated steatohepatitis MASH. This phase 3 study aims to compare pegozafermin against a matched placebo to better understand its effects on liver fibrosis and disease progression in this population. Participants will receive either pegozafermin or a placebo through subcutaneous injections. The study is randomized and quadruple-blinded, ensuring neither participants nor researchers know which treatment is given. Treatment effects will be observed over a period of up to 5 years, with primary outcomes measured at 24 months, including fibrosis regression and time to disease progression based on specified clinical events. Throughout the study, participants will undergo regular assessments, including liver function tests like ALT and AST, enhanced liver fibrosis scores, FibroScan elastography, and evaluations for portal hypertension and other liver-related complications. Safety monitoring will track adverse events during the treatment and follow-up period. The trial spans several years, allowing long-term observation of treatment outcomes and participant health.

Age: 18Years - 75YearsAll GendersPhase 3
330 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety and immune response of a group B streptococcus GBS vaccine in healthy pregnant women and their babies. This Phase 3 randomized, placebo-controlled, double-blinded study involves pregnant participants aged 49 or younger between 24 and 36 weeks of pregnancy, without major fetal abnormalities or infections such as HIV, syphilis, or hepatitis B. The study aims to understand how the GBS vaccine works and its safety profile for both mothers and infants. Participants will receive a single injection of either a multivalent GBS vaccine GBS6 or a placebo saline. After birth, a subset of infants will participate for up to 19 months, receiving standard vaccines including diphtheria toxoid-containing and pneumococcal vaccines as per local immunization schedules. Blood samples will be collected from infants after completing primary and booster vaccinations to assess immune responses. Pregnant participants will attend at least 3 to 4 visits with some allowed by telephone, with follow-up continuing for up to six months after delivery. Infants will be monitored for about 12 months, including a subset with extended follow-up to 19 months. Researchers will evaluate adverse events, antibody levels, and immune responses in both mothers and infants to assess safety and potential protection provided by the vaccine.

Age: 1Day - 49YearsAll GendersPhase 3
219 locations
S

Actively Recruiting

This research aims to compare two different approaches to post-hospitalization follow-up care for children hospitalized with common infections such as pneumonia, skin and soft tissue infections, acute gastroenteritis, or urinary tract infections. The study evaluates whether automatic follow-up visits scheduled at discharge or a more flexible as-needed PRN follow-up approach, where parents monitor symptoms and decide on visits, impact hospital readmission rates and other health outcomes. Participants are randomly assigned to one of two groups. One group receives a recommendation for automatic follow-up, instructing them to schedule and attend a follow-up visit regardless of symptom improvement. The other group receives a recommendation for PRN follow-up, where scheduling a visit at discharge is not required, and parents decide if a visit is necessary based on their childs symptoms. Both groups are monitored to compare outcomes over time. During the study, researchers will track hospital readmissions within 14 days of discharge as the primary outcome. Secondary outcomes include medical interventions and the childs health-related quality of life measured seven days after discharge. Additional factors like healthcare use, parent anxiety, satisfaction, and costs will also be assessed. The study includes follow-up through communications with healthcare providers and monitoring of immunizations and well-child visits. Participation lasts at least through the 14-day post-discharge period to capture these outcomes.

Age: 0 - 18YearsAll GendersPhase Not Applicable
14 locations
P

Actively Recruiting

Researchers are gathering information on children treated with radiation therapy for cancer to better understand the benefits and risks of different radiation methods, particularly proton beam radiation therapy PBRT. PBRT has shown promise in targeting tumors more precisely and causing fewer long-term side effects, but more data is needed to confirm these advantages. This registry study aims to collect detailed demographic and clinical data from multiple centers to support future research and collaboration. Participants will receive their cancer treatment as determined by their doctors, including any surgeries, chemotherapy, and radiation therapy. The study will record all treatments and monitor outcomes such as treatment response, side effects, and cancer progression. Data collected at screening includes patient demographics, diagnosis details, imaging, lab tests, and treatment history. Treatment data will track radiation doses, timing, and concurrent therapies. After treatment, participants will be followed annually to update their health status, including disease progression, hospitalizations, new medical conditions, medications, and long-term side effects like hearing or hormonal issues. Researchers will collect medical records and test results over time to understand short- and long-term effects of radiation therapy. This lifelong follow-up helps evaluate the outcomes of proton beam radiation therapy in children with cancer.

Age: 0 - 21YearsAll Genders
26 locations
C

Actively Recruiting

Researchers are investigating treatment options for people with active rheumatoid arthritis RA who have not responded well to a tumor necrosis factor inhibitor TNFi biologic medication. The study compares two treatment strategies switching to a non-TNFi biologic drug such as rituximab, abatacept, tocilizumab, or sarilumab versus switching to a targeted synthetic disease-modifying antirheumatic drug tsDMARD like tofacitinib, baricitinib, or upadacitinib. This research addresses a significant gap in knowledge as current guidelines recommend switching treatments but lack strong evidence comparing these options directly, especially regarding patient-reported outcomes PROs like function and quality of life. Participants will be randomly assigned to receive either a non-TNFi biologic or a targeted synthetic DMARD. The choice of specific medication within each class is based on what is available and accessible through insurance or patient assistance programs. The study follows a pragmatic design to reflect real-world treatment decisions and includes patients with comorbidities. Treatment continues with stable doses of certain conventional synthetic DMARDs if already being used. This head-to-head trial aims to provide comparative effectiveness data for these two treatment strategies over a 12-month period. During the trial, participants will be monitored for changes in functional limitations using the Health Assessment Questionnaire HAQ, a sensitive tool for measuring outcomes important to patients with RA. Researchers will also track treatment toxicity and quality of life changes. The study involves regular assessments over one year to evaluate the benefits and risks of each treatment approach, helping patients and providers make informed decisions based on outcomes that matter most to patients.

Age: 18Years +All GendersPhase 3
49 locations